The FDA's premarket cybersecurity guidance (Section 524B of the FD&C Act, effective October 2023) requires medical device manufacturers to submit cybersecurity documentation as part of their premarket submissions.
Our FDA cybersecurity practice helps medical device manufacturers, digital health companies, and IVD developers build and document the cybersecurity controls the FDA expects.
We bring a compliance-first approach grounded in NIST CSF 2.0, IEC 62443, AAMI TIR57, and the FDA's own guidance documents.
Frameworks: FDA Premarket Cybersecurity Guidance, NIST CSF 2.0, IEC 62443, AAMI TIR57, HIPAA, UL 2900
适用对象
- Medical device manufacturers preparing premarket submissions requiring cybersecurity documentation
- Digital health and SaMD companies building connected health platforms
- In vitro diagnostic (IVD) manufacturers with networked or cloud-connected systems
- Contract manufacturers and OEMs supplying components for connected medical devices
- Medical device companies that received FDA deficiency letters citing inadequate cybersecurity documentation
您将获得
- Threat modeling and cybersecurity risk assessment per AAMI TIR57 and FDA guidance
- Software Bill of Materials (SBOM) generation in SPDX or CycloneDX format
- Cybersecurity design documentation for premarket submissions
- Vulnerability assessment and penetration testing of device firmware, APIs, and cloud interfaces
- Patch and update management plan documentation
- Coordinated vulnerability disclosure (CVD) policy and process
- Postmarket cybersecurity surveillance program design
- Gap assessment against FDA premarket cybersecurity guidance and NIST CSF 2.0
- Remediation support for FDA deficiency letters related to cybersecurity
常见问题
通过渗透测试强化FDA 网络安全合规性
用真实攻击模拟验证您的安全控制措施。我们的OSCP认证从业者在外部网络、内部网络、Web应用、移动应用、API、IoT、无线网络和Red Team八个领域开展手动、方法论驱动的测试。
了解渗透测试